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Abstract (250 words) 27 
 28 
Background. 29 
Drug efficacy trials monitor the continued efficacy of front-line drugs against falciparum malaria.  30 
Over-estimates of efficacy result in a country retaining a failing drug as first-line treatment with 31 
associated increases in morbidity and mortality, while under-estimating drug effectiveness leads to 32 
removal of an effective treatment with substantial practical and economic implications. Trials are 33 
challenging: they require long durations of follow-up to detect drug failures, and patients are 34 
frequently re-infected during that period. Molecular correction based on parasite genotypes 35 
distinguishes reinfections from drug failures to ensure the accuracy of failure rate estimates. Several 36 
molecular correction “algorithms” are proposed, but which is most accurate and/or robust remains 37 
unknown. 38 
Methods. 39 
We used pharmacological modelling to simulate parasite dynamics and genetic signals that occur in 40 
patients enrolled in malaria drug clinical trials. We compared estimates of treatment failure 41 
obtained from a selection of proposed molecular correction algorithms against the known “true” 42 
failure rate in the model.  43 
Findings. 44 
(i) Molecular correction is essential to avoid substantial over-estimates of drug failure rates. (ii) The 45 
current WHO-recommended algorithm consistently under-estimates the true failure rate. (iii) Newly-46 
proposed algorithms  produce more accurate failure rate estimates; the most accurate algorithm  47 
depends on the choice of drug, trial follow-up length, and transmission intensity. (iv) Long durations 48 
of patient follow-up may be counterproductive; large numbers of new infections accumulate and 49 
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may be misclassified, over-estimating drug failure rate. (v) Our model was highly consistent with 50 
existing in vivo data. 51 
Interpretation. 52 
The current WHO-recommended method for molecular correction and analysis of clinical trials 53 
should be re-evaluated and updated. 54 
 55 
  56 
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1. Introduction 57 
 58 
Malaria is endemic in over 100 countries and causes an estimated 400,000 deaths per annum (1); 59 
most deaths are caused by Plasmodium falciparum and this study focusses on drug treatment of that 60 
species. Prompt treatment of malaria infections is an essential and effective public-health tool, but 61 
drug resistance poses a constant threat to effective treatment of falciparum malaria. The World 62 
Health Organization (WHO) currently recommends that endemic countries test their first- and 63 
second line antimalarial drugs every two years at sentinel sites to confirm their continued efficacy 64 
(2) and more frequently if resistance is suspected. The first line treatments in most malaria-endemic 65 
countries are artemisinin based combination therapies (ACTs), consisting of an artemisinin 66 
component (artesunate (AS), artemether (A or dihydroarteminisin (DHA)), which rapidly clears 67 
parasites and a ‘partner’ drug that ensures eventual parasite clearance and therapeutic cure (3, 4). 68 
The clinical consequence is that malaria infections fall rapidly to undetectable levels immediately 69 
after ACT treatment initiation. The partner drugs (mefloquine (MQ), lumefantrine (LF), piperaquine 70 
(PPQ), amodiaquine, sulphadoxine-pyrimethamine, pyronaridine) all have substantial half-lives. 71 
Infections surviving treatment are termed “recrudescences” and may only recover to densities 72 
sufficiently high to become detectable once partner drug concentrations have decayed to ineffective 73 
concentrations - potentially weeks after treatment. Anti-malarial drug efficacy studies therefore 74 
monitor patients for extended periods of time post-treatment to ensure recrudescences are 75 
detected. Duration of follow up depends on the half-life of the drug being assessed (2, 5), usually 76 
between 4 and 6 weeks (28 to 42 days) (3), sometimes extended to 9 weeks for research purposes. 77 
The critical operational problem is that new falciparum clones may be inoculated into patients by 78 
mosquitoes during these follow-up periods and these infections (termed “reinfections”) must be 79 
distinguished from recrudescence to allow accurate estimates of drug efficacy (Figure 1). This is not 80 
a trivial problem: Annual entomological inoculation rates (aEIR) of malaria, a measure of malaria 81 
exposure in a population, are typically >10 and >100 per patient in areas of moderate to high 82 
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transmission, respectively. Moderate to high transmission sites are preferred for clinical trials as 83 
morbidity from malaria is high, so trials cover the most at-risk patient populations, and, from a 84 
practical viewpoint, patient recruitment is straightforward.  85 
The consensus method for distinguishing recrudescence from reinfections is molecular correction or, 86 
equivalently, polymerase chain reaction (PCR)-correction. A genetic profile of the malaria infection 87 
of each patient is taken just before treatment, with a second profile taken if the patient develops a 88 
detectable malaria infection during follow-up (known as “recurrent” parasitaemia). If the profiles 89 
‘match’ then the patient is considered to have a recrudescent infection if they do not match the 90 
patient is considered to have a reinfection. This ‘matching’ is simple in principle, but in practice has 91 
substantial limitations. The main problem is that individual malaria infections may consist of several 92 
genetically-distinct clones. Current genotyping techniques struggle to detect minority clones that are 93 
present in relatively low numbers and/or which carry alleles that do not amplify well during the 94 
genotyping process. These limitations were recognised early in the development of molecular 95 
correction methodology (6-8) and led the WHO and Malaria for Medicines Venture (MMV) to co-96 
sponsor a meeting in 2007 to identify a consensus methodology for molecular correction; their 97 
findings were published in 2008 (3). Concerns surrounding the limitations of molecular correction 98 
have persisted (9, 10): Previous studies have noted that different algorithms give different results 99 
when applied to clinical data (e.g. Table 2 of (10)) and a recent publication quantifying the 100 
limitations inherent in PCR detection has led to renewed calls for this methodology to be re-101 
examined (11). There now exist several proposed sets of rules (referred to hereafter as 102 
“algorithms”), for interpreting genetic profiles to classify patients (Table 1). The true failure rate is 103 
unknown in vivo, so it has been impossible to identify which algorithm is most accurate; 104 
consequently, the molecular correction field is currently in a state of limbo with several alternative 105 
methods giving different results, but with no way of knowing which method is most accurate; 106 
furthermore, some of these algorithms are newly proposed and have not been used to return failure 107 
rate estimates in vivo. There is a clear need for greater precision and improved harmonisation in 108 
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molecular correction techniques. Pharmacological simulation methods can be used to recreate data 109 
from clinical trials: Since the true failure rate is known in silico, it is possible to quantify which 110 
algorithm provides the most accurate and/or robust method of analysis. The impact of drug efficacy 111 
trials is potentially enormous. Over-estimates of drug efficacy may result in a country retaining a 112 
failing drug as first-line treatment with associated increases in morbidity and mortality, while under-113 
estimating drug effectiveness may lead to removal of an effective first-line treatment with 114 
substantial practical and economic implications. 115 
 116 
2.  Methodology 117 
 118 
The World Health Organization (WHO) have published a standardised, “consensus” list of terms (12) 119 
which we have used throughout this work, with a key exception: Our key term “drug failure” is not 120 
equivalent to “treatment failure” because, according to the WHO definitions, late treatment failure 121 
(LTF) includes patients who either failed drug treatment (i.e., recrudescence) or acquired a 122 
reinfection during follow up (2, 12).  The unambiguous term “drug failure” will be used here to 123 
indicate that a patient’s initial infection was not cleared by drug treatment.  124 
 125 
To create a model with which to investigate the accuracy of molecular correction methods, we used 126 
a two-stage process implemented in the statistical programming language R (version 3.5.1) (13).  127 
1. Use pharmacological modelling to simulate the parasite dynamics post-treatment in a 128 
population of patients enrolled in a clinical trial and track subsequent intra-host P. falciparum 129 
dynamics in these patients post-treatment. 130 
2. Allocate genetic signals to each simulated parasite clone and calculate the genetic signals 131 
detected from a patient’s blood sample at a given follow-up day (dependent on a variety of 132 
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factors, explored later), then analyse these signals using different algorithms (Table 1) to classify 133 
recurrent infections as drug failures or reinfections. This classification was used to generate drug 134 
failure rate estimates with comparison to true drug failure rates; thus, determining if 135 
improvements in the accuracy of these estimates were obtainable through adoption of novel 136 
algorithms.  137 
Malaria parasite dynamics were generated using pharmacological models of malaria drug treatment 138 
that have been developed over the last decade (e.g. (14-21)) and previously calibrated and validated 139 
for three front-line ACTs: Dihydroarteminisin-Piperaquine (DHA-PPQ), Artemether-Lumefantrine 140 
(AR-LF) and Artesunate-Mefloquine (AS-MQ). The key advantage of this approach was that the exact 141 
parasitaemia of each malaria clone in each simulated patient at each time point post-treatment was 142 
known (Figure 1), as was the true status (i.e. recrudescent or reinfection) of any recurrent infection 143 
that occurred in that patient. This allowed testing of how well different PCR correction algorithms 144 
classified recurrent infections as “drug failures” or “reinfections”. It also meant the true failure rate 145 
of the drug in the simulated trial was known, as this could be calculated directly from models of 146 
parasite dynamics (i.e., did all the initial clones clear by the final day of follow-up?). This allowed 147 
each algorithm to be tested for accuracy against the true failure rate in the simulation.  148 
2.1 Generation of parasite dynamics post-treatment using pharmacokinetic/pharmacodynamic 149 
(PK/PD) models  150 
Parasite dynamics were generated using existing pharmacokinetic/pharmacodynamic (PK/PD) 151 
models; these models have been calibrated and validated for a range of ACTs and successfully used 152 
to investigate a variety of key research questions (14-18, 22, 23). The PK/PD parameters used to 153 
generate these dynamics for each ACT are described in full in Supplemental Material [SM]. It is 154 
important to note that our results were not dependent on any choice of calibration. A full discussion 155 
of the variation that use of different PK and PD parameters would induce in our results is included in 156 
[SM]. Variation was included for all parameters, and we later show that our findings with regards to 157 
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the relative performance of the molecular correction algorithms were consistent across three 158 
different ACTs, multiple PD parameterizations (i.e., changing IC50 to simulate failing / non-failing 159 
drugs) and for both a two-compartment and three-compartment model of DHA-PPQ (explored 160 
extensively in [SM]).  Thus, we are confident that PK/PD models of DHA-PPQ, AR-LF and AS-MQ were 161 
appropriate means by which to generate parasite dynamics post-treatment for the purposes of this 162 
study.  Alternative methods were available, i.e. arbitrarily constructing recurrent infections as 163 
containing a given proportion recrudescent and/or reinfection, and testing the algorithms’ ability to 164 
correctly classify them (as is routinely done to construct laboratory mixtures e.g. (11)), or setting 165 
distributions of time until recrudescence and/or reinfection and using these distributions to 166 
construct recurrent infections.    However, the use of an explicit PK/PD model added an additional 167 
level of realism to these arbitrary approaches: it was simple, easily scalable, more realistic and 168 
allowed for future tuning and testing if novel parameterizations emerge within the field for these 169 
and for other antimalarial drugs.  170 
While it was obviously not feasible for us to simulate and present every possible parameterization to 171 
create parasite dynamics likely to occur in trials (though note our included variation covers a large 172 
range of possible values), calibrating the models to re-run a specific set of parameters for interested 173 
groups is a simple task upon provision of the parameters.  174 
2.1.1 Number of malaria clones per patient 175 
A malaria infection may consist of several genetically-distinct parasite clones and the number of 176 
clones in a patient at the time of treatment is termed the multiplicity of infection (MOI). Two MOI 177 
distributions were used in our models. A “high MOI” representative of the MOI in an area of intense 178 
transmission, in this case Tanzania  where MOIs of 1-8 were assigned with probabilities 0.036, 0.402, 179 
0.110, 0.110, 0.183, 0.049, 0.061, 0.049 respectively (24). A  “low MOI”  distribution was based on 180 
data from Papua New Guinea with probabilities of 0.460, 0.370, 0.150 and 0.020 for an MOI of 1-4 181 
respectively (25); these two distributions were used  to check if the accuracy of different algorithms 182 
 o
n
 July 24, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
10 
 
were consistent across different MOIs. Each clone within the MOI (later called “initial clones”) had 183 
their starting parasitaemia drawn from a log-uniform distribution spanning from 1010 to 1011 asexual 184 
parasites per person. Previous modelling approaches (25) used 1012 parasites as the upper limit of 185 
parasitaemia because this level of parasitaemia is likely to be lethal or at least be a parasite density 186 
sufficiently high that such patients would not be enrolled in a clinical trial; hence 1011 was used as 187 
the upper limit for any single clone at the time of treatment. 188 
Reinfections emerging from the liver are illustrated as the grey and orange dotted lines in Figure 1. 189 
Reinfections were assumed to emerge from the liver with a parasitaemia of 105 and all drugs 190 
modelled were assumed to be inactive against the hepatic stages. The rate of emergence reflected 191 
the local intensity of malaria transmission and was quantified as the “Force of Infection” (FOI). At the 192 
start of the model, each patient was assigned the number of reinfections that would emerge during 193 
a year. This number was drawn from a Poisson distribution whose mean value was the FOI. Values 194 
for FOI from 0-16 were used to reflect low, medium, and high transmission areas; as a general guide 195 
we regarded FOI≤2 as representing a low transmission setting, 2<FOI≤8 as indicative of moderate 196 
transmission intensity, and FOI>8 as high transmission; the yearly value was then converted to the 197 
number of reinfections occurring during the follow-up period. See [SM] for a detailed discussion of 198 
FOI values.  199 
2.1.2 Tracking  parasite numbers (parasitaemia) over time 200 
Multiple lengths of follow-up are permitted in the WHO guidelines (3) and used in practice (26). The 201 
length of the follow-up period affects drug failure rate estimates in two ways: Firstly, a longer follow-202 
up period will allow more time for recrudescent clones to become detectable (i.e. if a patient had 203 
parasites that would recrudesce and become detectable on day 60 and the follow-up period was 28 204 
days, this recrudescence would not be observed). Secondly, a longer follow-up period leads to more 205 
reinfections emerging in each patient, some of which may be misclassified as recrudescence and 206 
inflate failure rate estimates. Accurate, robust analyses need to balance these two risks through 207 
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appropriate choice of follow-up duration. WHO guidelines (2) stipulate that patients are checked for 208 
recurrent parasitaemia by light microscopy on scheduled days of follow-up. A 28-day follow-up 209 
schedule requires patients be examined on days 3, 7, 14, 21 and 28. A 42-day follow-up period uses 210 
two additional days i.e. days 35 and 42. A 63-day follow-up period (not recommended in routine 211 
surveillance) has scheduled visits as per the 42 days but with 3 extra days i.e.  49, 56 and 63. Novel 212 
lengths of follow-up were simulated simply by “ending” the trial on any given day of follow-up, i.e. to 213 
investigate a 35-day follow-up length, patients were checked on days 3, 7, 14, 21, 28 and 35.  214 
The parasitaemia of each clone in each patient was tracked and updated each day to reflect two 215 
factors. First, the extent of drug killing based on the PK/PD parameters (see calibration of PK/PD 216 
parameters in Table S1); second, the growth rate of each clone, which was assumed to be identical 217 
for every clone and set to 1.15/day as in previous modelling work (14, 27). The model assumed that 218 
if the total parasitaemia (i.e. the sum of parasitaemia of all clones) in a patient at any time, reached 219 
1012, then density-dependent effects, such as fever, set the growth rate of every clone to 0.   220 
The model checked each day of scheduled follow-up to determine whether a patient had enough 221 
parasitaemia that a recurrence would be detectable by light microscopy (a recurrence) – 222 
parasitaemia was considered detectable if the total number in a patient was ≥ 108 on that day.  We 223 
note that variance in the limit of detection by light microscopy exists with respect to the skill of the 224 
microscopist (28); we have chosen here to assume this limit reflective of an “expert” microscopist 225 
(corresponding to roughly 20 parasites /  μl of blood).  226 
2.2 Allocation and analysis of genetic data  227 
Each clone, whether an initial clone present at treatment or a reinfection that emerged during the 228 
follow-period, was assigned a genetic profile based on three markers: msp-1, msp-2, and glurp, using 229 
previously established distributions for the frequency of alleles. Msp-1 and msp-2 allelic frequency 230 
distributions and amplicon sizes were derived from 115 or 108 patients from Tanzania (29). Glurp 231 
distributions were drawn from a collection of field samples described in (11). The length of each 232 
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allele and its allelic family (for msp-1 and msp-2) was also noted. The distributions we used gave 233 
msp-1 expected heterozygosity (He) of 0.915, msp-2 He of 0.963, glurp He of 0.956; [Supplemental 234 
File 1] for full data). It was assumed that the genotypes of initial clones were independent of each 235 
other and were also independent of the genotypes of reinfections (i.e. it was assumed there is no 236 
local genetic structuring of the malaria population). Note that alleles at msp-1 and msp-2, exist in 237 
our distributions as members of three or two distinct families, respectively.  238 
Once the patient parasite dynamics were modelled (as described above), and genetic profiles at the 239 
three loci were assigned, our models followed the same process as in vivo trials.  Blood samples 240 
were taken from each patient immediately prior to treatment (the initial or “baseline” sample), and 241 
at pre-determined days during the follow-up period. Samples were screened for the presence of 242 
Plasmodium falciparum by light microscopy and any detected infection is labelled a “recurrence”. 243 
We simulated the genotyping that would be used in vivo to obtain the genetic profiles for all initial 244 
and recurrent infections.  Recovering the genetic signal that would be observed at time of treatment 245 
and at any recurrence reflected the technical limitations of acquiring blood samples and genotyping 246 
as follows:  247 
 A “sampling limit” exists; a finite amount of blood is used for genotyping. A parasite clone 248 
(and consequently, it’s alleles) would not be detected if its density were so low that no 249 
parasites are included in the blood sample analysed.  Thus, the density and volume of the 250 
processed blood sample define the limit of detection. Obviously, this sampling limit differs 251 
between methods and laboratories. Typically, the equivalent of 1 μl of whole blood is 252 
introduced into PCR.  Assuming 5 L of blood in the human body gives a total of 5 x 106 μl of 253 
blood, For a clone to be detected a minimum of 1 parasite (which carries a single DNA 254 
template) would need to be present in 1 μl of blood so there would need to be at least 5 x 255 
106 of a given clone present for that clone to be physically sampled in the genotyping 256 
process and we also needed to allow for the fact that sub-optimal storage conditions (such 257 
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as temperature) frequently occurs in the field and will lead to DNA template breakages, and 258 
there is periodical absence from the peripheral blood of sequestered parasites. 259 
Consequently, the limit of detection will be much higher than 1 parasite per 1μl of blood. 260 
We therefore assumed 10 to 20 parasites per μl  would be required to reliably contribute a 261 
genetic signal and ensure its detection, corresponding to a total parasitaemia of 5 x 107 to 262 
108; we selected the upper limit i.e. 108, to ensure reliable detection of that clone and 263 
because it is consistent with the microscopy  detection limit. 264 
 The magnitude of the genetic signal that will be produced by each malaria allele in the blood 265 
sample was proportional to the number of parasites carrying that allele. 266 
 An inherent feature of PCR is “template competition” i.e. the relative detectability of alleles 267 
at each marker depended on their length, with shorter length alleles being more detectable 268 
due to their being better amplified in the PCR process (11) . A linear relationship between 269 
allele length and relative detectability was assumed; this was done for simplicity but other 270 
relationships, for example log-linear, could also be investigated. The shortest allele in each 271 
case was assumed to have a relative detectability of 1 while the longest had a relative 272 
detectability of 0.001 i.e.  we assumed the shortest allele generated a thousand times the 273 
genetic signal of the longest. This number is based on calculations from (11). Families within 274 
msp-1 and msp-2 were assumed to be amplified by separate reactions (i.e. are not 275 
multiplexed), so the effect only occurred between alleles within the same families (glurp 276 
does not have families so the effect applied to all alleles). The sensitivity of the results to this 277 
relative detectability was tested by shortening it to 0.1, see [SM]; we later show that it does 278 
not affect our results.  279 
The strength of the genetic signal contributed by an allele in a given blood sample was therefore the 280 
product of two factors: The number of parasites carrying the allele times the detectability of the 281 
allele.  Note that genotyping detects alleles, not parasites. Hence, if two (or more) clones within the 282 
infection shared the same allele, the signal for that allele was based on the total number of parasites 283 
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in the two (or more) clones. The final step is to recognise that, in practice, if one allele makes up a 284 
large proportion of the genetic signal, then the smaller signals from ‘minority’ alleles would be 285 
rejected as background “noise”. We assumed this threshold to be 25% i.e. that signals from alleles 286 
that were less than 25% of the highest allelic signal are rejected as “noise”, though we test other 287 
values of this parameter [SM].  288 
We do not explicitly incorporate the effect of malaria sequestration in our simulations. Sequestered 289 
stages are not detectable in blood so if a malaria clone is asynchronous in its 48 hours of 290 
development, its detectability will differ over consecutive days (30, 31), hence the observation that 291 
sampling blood from a patient on two consecutive days greatly improves the genetic detectability of 292 
clones in the patient (32, 33). WHO recommend single-day sampling, presumably for logistical 293 
reasons and because of ethical considerations to treat infections as soon as possible. We do not wish 294 
to enter the debate about the practicality vs desirability of single or consecutive-day sampling but 295 
simply note that our results apply to both methodologies. The effect of consecutive-day sampling is 296 
to improve genetic detectability of clones and sensitivity analysis of our detection limit (SM; Figure 297 
S11) shows that improved detectability does not qualitatively affect our conclusions. 298 
 299 
2.3. Classifying patients according to therapeutic outcome in trials. 300 
 301 
Analysis of parasitaemia during patient follow-up and, if required, application of molecular 302 
correction algorithms to recurrent infections. Four molecular correction algorithms (and a non-PCR 303 
corrected “algorithm”) were investigated. The current “WHO/MMV” algorithm (3), a “no glurp” 304 
algorithm that only considers msp-1 and msp-2, a  “≥ 2/3 markers” algorithm that considers msp-1, 305 
msp-2 and glurp but requires matching alleles at only two markers to classify a recrudescence, and 306 
an “allelic family switch” algorithm that considers only msp-1 and msp-2 and requires a family shift 307 
to classify a recrudescence if the markers are discordant (i.e., one has shared alleles between the 308 
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initial and recurrent infections and one does not). Full details of these algorithms are presented in 309 
Table 1; they enabled each patient to be classified across four groups as would occur in a real trial 310 
i.e.  311 
(i) An early treatment failure (ETF) if a recurrence occurs on or before day 7; note that all 312 
such recurrences are regarded as drug failures and molecular correction is not required. 313 
In our simulations, on day 3, if total parasitaemia exceeded 108 but was <25% of the 314 
total parasitaemia of the initial sample, the patient continued in the trial per the WHO 315 
protocol (consequently, no genotype was taken of the day 3 sample and no classification 316 
was made); if parasites were present at >25% of initial parasitaemia, that patient was 317 
classified as an early treatment failure, consistent with the WHO procedure (2) . For the 318 
purposes of estimating failure rates in this methodology, we do not distinguish between 319 
early treatment failure and recrudescence as both are indicative of drug failure.  320 
(ii) A drug failure if a recurrence was classified as such by a PCR-correction algorithm on 321 
Table 1. 322 
(iii)  A reinfection if a recurrence was classified as such by a PCR-correction algorithm on 323 
Table 1. 324 
(iv) ‘Cleared’ i.e.  no recurrent parasitaemia was detected during follow-up; in these cases, 325 
the drug was assumed to have successfully killed all parasites present at time of 326 
treatment. 327 
 328 
A key objective of this paper was to investigate how well the classification algorithms applied to 329 
recurrent infections (Table 1) recovered the true status of recurrent infections. We therefore 330 
defined the latter according to parasitaemia data from the PK/PD model (Figure 1). 331 
 True recrudescence was defined as a recurrent infection that contained at least 108 332 
parasites from a clone present at time of treatment (this patient is, by definition, a drug 333 
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failure). This included patients who have a ‘mixed’ infection on the day of recurrence i.e. 334 
possessed malaria clones that survived treatment plus reinfection clones that were 335 
acquired during follow up, providing the former exceed 108; note that all clones 336 
contributed to the genetic signal of the recurrence as described above. 337 
 True reinfection was defined as a recurrent infection whose blood sample contained 338 
only parasites from clone(s) that were reinfection(s) (note that such patients may 339 
harbour parasites from original clones if these clones were sub-patent i.e. less than 108 340 
parasites).  341 
 342 
It was possible that recrudescent clones may not have reached microscopically detectable levels (i.e. 343 
parasite numbers are <108) on the final day of follow-up; such patients would be classified as 344 
“cleared” in vivo and thus, a treatment success. However, simulated data have confirmed that it is 345 
possible for some patients to still harbour parasites below detection level at the end of follow up 346 
(23). Our modelling approach classifies these patients as drug failures.  347 
Note there are only a finite number of alleles at each locus and, thus, two distinct clones of malaria 348 
may have had identical allele(s) at one or more marker purely by chance. It followed that 349 
reinfections and recrudescences could share alleles, so misclassification of reinfection as 350 
recrudescence was possible.  351 
2.4. Estimating drug failure rates in the simulated trials 352 
 353 
The model was run for a cohort of 5,000 patients (although any number can be simulated). This is an 354 
unrealistically high number for an in vivo clinical trial but is ideal for our purposes: A true drug failure 355 
rate of 10-12% provided a large number of recurrences (the exact number varied depending on the 356 
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ACT, FOI, and length of follow up) that we can test against the various classification algorithms and 357 
reduces the uncertainty around results.  358 
The four patient outcomes described above were used to calculate the estimated drug failure rate, ?̂? 359 
in the same manner as outcomes reported in vivo). It was assumed, for simplicity, that no patients 360 
were lost to follow-up or removed from the trial for any reason other than recurrent parasitaemia. 361 
There were three methods for calculating failure rates which differed in how they processed patients 362 
with recurrent parasitaemia that had been classified as reinfections, noting that all patients with 363 
recurrent parasitaemia would, in vivo, be re-treated with another antimalarial (for ethical reasons) 364 
and removed from the trial. The three methods were: A non-PCR corrected failure rate, a “per 365 
protocol” failure rate and a failure rate obtained using survival analysis. The latter two methods are 366 
recommended by the WHO to analyse anti-malarial drug trials (2, 3). Technically, they were 367 
calculated as follows using the following nomenclature: 368 
 𝐶𝑜 was the number of patients who cleared infection.  369 
 𝑛𝐼𝑜, was the number of patients whose recurrent infections were classified as reinfections.   370 
 ?̂? was the estimated drug failure rate.  371 
N was the total number of patients.   372 
(i) The non-PCR corrected failure rate was obtained by considering all patients with recurrent 373 
infections as patients who had failed drug treatment. This method did not require distinguishing 374 
between reinfections and recrudescent infections. The failure rate  ?̂? could then be estimated as:  375 
 376 
?̂? = 𝟏 −
𝑪𝒐
𝑵
            Equation 1 377 
 378 
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(ii) The ‘per protocol’ method, recommended by WHO (2, 3, 5), simply removed patients who were 379 
classified as reinfections from the total number of observations i.e.: 380 
?̂? = 𝟏 −
𝑪𝒐
𝑵−(𝒏𝑰𝒐)
                 Equation 2 381 
 382 
(iii) Survival analysis, as recommended by WHO (3), used the survivor function from a Kaplan Meier 383 
plot on the final day of follow-up, right-censoring reinfections.  384 
The Kaplan-Meier estimator KM of survivorship at time t was obtained as:  385 
?̂?(𝒕) =  ∏
𝒏𝒊−𝒅𝒊
𝒏𝒊𝒕𝒊≤𝒕
                   Equation 3386 
  387 
 388 
Where t was a vector of all timepoints i.e. days of follow-up in which an event occurred in the study 389 
population, ni was the number of individuals at time ti who remained uninfected, and di was the 390 
number of events (drug failures in this case) that occurred at timepoint ti. Plainly, what this method 391 
did was calculate the proportion of patients who remained free of recrudescence between 392 
consecutive days of follow up, then multiplied all these time periods to obtain the overall probability 393 
of ‘surviving’ recrudescence-free over the whole follow-up period. The advantage was that even 394 
those patients who are “censored” (by acquiring a reinfection and leaving the study) will still 395 
contribute to the analysis through their inclusion prior to their removal.  396 
The estimator at the final time-point (i.e. the last day of follow-up) was the probability that their 397 
treatment was considered a ‘success’ at the end of the trial. Consequently, it’s complement gave the 398 
probability that a given individual will fail treatment i.e. 399 
?̂? = 1 − ?̂?(𝑡)                      Equation 4 400 
 401 
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The final methodological step was to interrogate the modelled data to determine the “true failure 402 
rate” – i.e., the drug failure rate calculated directly from the parasitaemia of each patient (thus, not 403 
dependent on genotyped data). For each patient in the simulation, an outcome on the final day of 404 
follow-up was determined: If, on the final day, the patient had any parasites from any initial clones 405 
(i.e. even a single parasite), the patient was denoted as a drug failure. If no parasites had survived 406 
from the initial clones present at treatment, that patient was denoted as a treatment success.  407 
The true failure rate, F, for the patient population was then calculated:  408 
𝐹 =
𝑓
𝑁
           Equation 5 409 
Where f was the number of drug failures on the final day of follow-up and N was the total number of 410 
patients.  411 
This was the “gold standard” metric and cannot be obtained in vivo. It was compared to the 412 
estimated failure rates obtained from modelling the clinical trial and molecular correction process 413 
and allowed us to quantify the accuracy of different methods (i.e., their ability to recover the true 414 
failure rate).  415 
2.5 Reanalysis of existing in vivo data 416 
Clinical data was obtained from Rwanda (a relatively high transmission area) across 6 sites between 417 
2013 and 2015, where patients were treated with either AR-LF or DHA-PPQ and genotyped at msp-1, 418 
msp-2 and glurp. In patients treated with AR-LF, 137 recurrences were observed, of which 110 could 419 
be classified as either a reinfection or a recrudescence (it was not possible to classify 27 patients 420 
because they had incomplete genetic data). In patients treated with DHA-PPQ, 48 recurrences were 421 
observed, of which 43 could be classified as either a reinfection or a recrudescence (it was not 422 
possible to classify 5 patients because they had incomplete genetic data). This data was initially 423 
presented internally to the National Malaria Control Programme in Rwanda (a manuscript describing 424 
clinical efficacy studies for publication is pending). 425 
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Clinical data from Cambodia (a relatively low transmission area) was obtained from 6 sites between 426 
2014-2016. Patients were treated with either artesunate plus amodiaquine (AS-AQ), artesunate plus 427 
pyronaridine (AS-PYN) or DHA-PPQ, and genotyped at msp-1, msp-2, and glurp. In patients treated 428 
with AS-AQ, 12 recurrences were observed, of which 5 could be classified as reinfection or 429 
recrudescence (7 patients had incomplete genetic data). In patients treated with AS-PYN, 14 430 
recurrences were observed, of which 12 could be classified as reinfection or recrudescence (2 had 431 
incomplete genetic data). In patients treated with DHA-PPQ, 67 recurrences were observed, of 432 
which 48 could be classified as reinfection or recrudescence (19 had incomplete genetic data). This 433 
data was initially presented internally to the National Malaria Control Programme in Cambodia. A 434 
description of the AS-PYN trials has already been published (34).  435 
For all data, the genetic signals (i.e., the msp-1, msp-2 and glurp alleles at the initial sample and any 436 
recurrent sample) were re-interpreted using the novel molecular correction algorithms described in 437 
Table 1 to investigate how varying the molecular correction algorithm changed the classification (as 438 
reinfection or recrudescence) of patients and, consequently, failure rate estimates.  439 
2.6 Data Availability 440 
The R code used to generate the results describe herein is available from the authors. The re-441 
analysed trial data-sets are likewise available from the authors.  442 
3. Results 443 
 444 
We identified several types of misclassification of recurrent infections in our experiments: 445 
1. Recrudescent infections could be misclassified as reinfection if the recrudescent allele(s) 446 
were not detected during the genotyping of the initial infection i.e. for example they were 447 
“minority alleles” (see methods). 448 
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2. A recrudescent infection could be misclassified as a reinfection if the recrudescent allele(s) 449 
were not detected during the genotype of the recurrent infection i.e. for example they were 450 
“minority alleles” (see methods).  451 
3. A reinfection could be misclassified as recrudescent if it shares (by chance) alleles with 452 
clones present at time of treatment. The exact number (or type) of alleles that must be 453 
shared depended on the molecular correction algorithm chosen (i.e., the “no glurp” 454 
algorithm was not affected by sharing an allele at glurp, and the “allelic family switch” 455 
algorithm was sensitive to sharing an msp-1 or msp-2 family by chance, whereas the other 456 
algorithms were not).  457 
While not misclassification of recurrence, another source of bias affected the accuracy of failure rate 458 
estimates with respect to the true failure rate: 459 
 A patient who failed to clear their initial infection may have had that infection persisting at a 460 
low-lying level, below the limit of detection of detection of light microscopy (assumed, see 461 
later, to be 108 total parasites in all clones), and have no reinfection, such that parasites 462 
were never detected during follow-up (and thus, no recurrent sample was genotyped); this 463 
obviously depends on the duration of follow-up.  464 
 465 
3.1 Impact of Algorithm choice on failure rate estimates 466 
 467 
Figure 2 shows the failure rates obtained from simulated DHA-PPQ clinical trials using four molecular 468 
correction algorithms and the non-corrected algorithm (Table 1), with a follow-up length of 42 days. 469 
Both the true failure rate and the estimated failure rate are presented (calculated using survival 470 
analysis) as a function of FOI.  471 
 472 
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The non-corrected algorithm always produced a higher failure rate estimate than any of the four 473 
molecular correction algorithms (Figure 2). Failure rate estimates using no correction rose rapidly as 474 
FOI increased and at moderate and high levels of transmission estimated failure rates were 475 
substantially greater than the true failure rate: At high transmission intensities (FOI of 16) estimated 476 
failure rates produced by this algorithm were above 50% - a clear over-estimate of the true failure 477 
rate (12%): This pattern occurred because all the additional reinfections that occurred at as FOI 478 
increased were misclassified as recrudescence. Conversely, in the absence of any reinfections (when 479 
FOI=0), the non-corrected algorithm produced an accurate failure rate estimate by correctly 480 
classifying all recurrences as recrudescence (leaving only a slight under-estimate due to patients who 481 
had recrudescent parasites at levels of <108, such that no recurrence occurred during follow-up). 482 
 483 
The ability of the four molecular correction algorithms to accurately estimate drug failure rates 484 
depended on their ability to correctly classify recrudescences and reinfections. This ability is shown 485 
(for an FOI of 8, i.e. a moderate transmission area) in Figure 3. Each algorithm misclassified some 486 
proportion of recrudescences and reinfections. The number of recrudescence misclassified as 487 
reinfections was consistent as FOI changed, but the number of reinfections misclassified as 488 
recrudescence increased as FOI increased – results shown in [SM] (note that while results for all 489 
parameterizations of AR-LF, AS-MQ and DHA-PPQ are not shown, the proportion of misclassification 490 
was extremely robust between drugs).  General trends were extremely clear: 491 
 492 
 The “WHO/MMV” algorithm consistently under-estimated failure rates at all transmission 493 
intensities as shown in Figure 2. The algorithm frequently failed to detect drug failures i.e. it 494 
misclassified around 40% of recrudescent infections as reinfections (Figure 3). These 495 
misclassifications occurred because of failure to detect recrudescent alleles in either the 496 
initial or recurrent blood sample – this algorithm was so stringent (requiring matching alleles 497 
at all three markers) that even missing a single allele could result in misclassification. As FOI 498 
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increased, the estimated failure rate did not change to any meaningful extent because the 499 
algorithm correctly classified nearly all reinfections (Figure 3).  500 
 501 
 The “no glurp” algorithm produced slightly higher estimated failure rates than the 502 
“WHO/MMV” algorithm across all FOI settings (Figure 2). This occurred because 503 
recrudescences were slightly less likely to be misclassified as reinfections while reinfections 504 
were slightly more likely to be misclassified as recrudescences than under the “WHO/MMV” 505 
algorithm (Figure 3). At low FOI, this difference was small; the high allelic diversity of msp-1 506 
and msp-2 meant misclassification of reinfections as recrudescences was rare. The 507 
difference between the “no glurp” algorithm and the “WHO/MMV” algorithm increased as 508 
FOI increased, but, like the “WHO/MMV” algorithm, the “no glurp” algorithm always under-509 
estimated the true failure rate.  510 
 511 
 The “≥ 2/3 markers” algorithm produced higher estimated failure rates than the “no glurp” 512 
algorithm across all FOI levels. This occurred because this algorithm reduced the chance of a 513 
recrudescence being misclassified as reinfection (due to failure to detect recrudescent 514 
alleles) and increased the chance of a reinfections being misclassified as a recrudescence 515 
(Figure 3). Both effects occurred because only needing matching alleles at 2/3 markers gave 516 
the algorithm some tolerance to un-detectable alleles.  517 
 518 
 The “allelic family switch” algorithm produced higher estimated failure rates than the “≥ 2/3 519 
markers” algorithms at all but the lowest FOI (0-2) settings (Figure 2). A complete family 520 
switch in msp-1 or msp-2 in a discordant sample (Table 1) would be sufficient to classify a 521 
recrudescence; this led to a similar number of recrudescence being correctly classified as the 522 
“≥ 2/3 markers”  algorithm, but this algorithm misclassified the largest number of 523 
reinfections as recrudescence out of all the molecular correction algorithms – the family 524 
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switch could still occur (by chance); the difference in numbers misclassified between the “no 525 
glurp” algorithm and the “allelic family switch” algorithm is the result of this misclassification 526 
by chance.  527 
 528 
 529 
3.2 Impact of follow-up length on failure rate estimates 530 
 531 
Alternate durations of follow-up length were simulated for DHA-PPQ and their impact on estimated 532 
failure rates are shown in Figure 4 for 28, 42 and 63 days of follow-up.  Longer durations of follow-up 533 
led to larger estimated failure rates for all algorithms. This occurred because longer follow-up (i) 534 
allowed more time for recrudescences to become detectable, (ii) allowed more reinfections to 535 
emerge, some of which were misclassified as recrudescences (Figure 3).  536 
 537 
Under-estimation of the true failure rate occurred with all algorithms when a 28-day follow-up 538 
period was chosen. With a 42-day follow-up period, the “allelic family switch” algorithm produced 539 
the most accurate failure rate estimate with an FOI of <7, and the “≥ 2/3 markers” algorithm 540 
produced the most accurate failure rate estimate with FOI ≥7. As length of follow-up increased to 63 541 
days, the “≥ 2/3 markers” algorithm tended to slightly over-estimate the failure rate. This effect was 542 
more apparent as FOI increased.  These patterns emerged because only a small number of initial 543 
clones recrudesced after 42 days. Figure 5 shows the proportion of recurrent infections on each day 544 
of the follow-up period that were truly recrudescent or reinfections. On days 49, 56 and 63, the 545 
number of recurrent infections that were truly recrudescent was small. Almost all recurrent 546 
infections on these days were reinfections and consequently, inclusion of these three extra days of 547 
follow-up inflated the estimated failure rate due to misclassification of these reinfections as 548 
recrudescences (as alleles were shared by chance between these reinfections and the initial blood 549 
sample).  However, the increased failure rate of a 42 day follow-up compared to a 28 day follow-up 550 
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(due to both detection of true recrudescence and misclassification of extra reinfections) meant that 551 
a 42 day follow-up period analysed with either the “≥ 2/3 markers” or “allelic family switch” 552 
algorithm produced more accurate failure rate estimates than the “WHO/MMV” algorithm.  553 
 554 
3.3 Results for other drugs / parameterizations / model settings  555 
 556 
Additional models for other ACTs are described in [SM]. In brief these drugs differed from DHA-PPQ 557 
mainly in their persistence of active drug concentrations post-treatment (and hence in their 558 
prophylaxis against reinfections). Results for failing AR-LF and AS-MQ were highly consistent with 559 
those described above for DHA-PPQ, showing the same qualitative patterns (i.e., that failure rate 560 
estimates increase as FOI increases and as the follow-up period increases, that the WHO/MMV 561 
algorithm under-estimates, that no correction leads to large over-estimates and that the “≥ 2/3 562 
markers” algorithm was generally accurate across a range of FOI values).  563 
 564 
Different prophylactic profiles meant that the most effective duration of follow-up for AR-LF and AS-565 
MQ (as would be expected) differed to DHA-PPQ; using the “≥ 2/3 markers” molecular correction 566 
algorithm, a 28 day follow-up for AR-LF appeared to be most accurate at moderate to high FOI. A 49 567 
day follow-up for AS-MQ appeared to be the most accurate with the “≥ 2/3 markers” algorithm but 568 
increased accuracy over using the “WHO/MMV” algorithm was also seen with using shorter follow-569 
up periods.  570 
 571 
Models of non-failing (i.e. clinically effective) PK/PD calibration of AR-LF and AS-MQ showed that the 572 
“≥ 2/3 markers” algorithm slightly under-estimated true failure rate but that this difference was 573 
small and there is no evidence that this algorithm would incorrectly identify effective drugs as 574 
failing.  575 
 576 
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Alternative parasite dynamics for DHA-PPQ were generated using a three-compartment model with 577 
PK parameters described in (35) to reflect to uncertainty  around how PPQ should be modelled (we 578 
previously identified and analysed 6 published and distinct PK calibrations for Piperaquine (23));note 579 
that PD parameters remained as for the two-compartment assumption, as described in [SM]). 580 
Parasite dynamics obtained using this three-compartment calibration resulted in a more 581 
prophylactic drug (i.e., fewer reinfections became patent) with a lower true failure rate (10%, with 582 
unchanged PD parameters). The relative failure rate estimates of the algorithms and the no-583 
correction approach were the same – i.e., that “WHO/MMV” algorithm produces the lowest failure 584 
rate estimate, followed by “no glurp”, “≥ 2/3 markers”, and the allelic family switch algorithm. 585 
Failure rate estimates are lower across all algorithms than with the shorter-prophylaxis two-586 
compartment model, and a 63-day follow-up appears to be the most suitable under this calibration; 587 
the “≥ 2/3 markers” algorithm produced an accurate failure rate estimate at all but the lowest FOI 588 
levels with this follow-up length). Crucially, the key message is the same: The WHO/MMV algorithm 589 
under-estimates true failure rate and other algorithms can produce more accurate failure rate 590 
estimates. Perhaps the most interesting difference between the two DHA-PPQ PK/PD calibrations is 591 
that they suggested, given use of the same molecular correction algorithm, different optimal length 592 
of follow-up. 593 
 594 
Failure rate estimates were calculated using the per-protocol method (methods) rather than survival 595 
analysis. The per-protocol method led to increased failure rate estimates with all algorithms, all ACTs 596 
and all follow-up periods. These results are discussed in [SM].  597 
 598 
Finally, the simulation was validated by varying the multiplicity of infection (MOI) at time of 599 
treatment, the relative detectability of alleles based on length, and the minority allele detection 600 
threshold. The results of these analyses are provided in [SM] and showed mostly the same 601 
qualitative patterns as the results presented above; the one key departure was that assumption of a 602 
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minority allele threshold of 5% (reduced from the assumption of 25%, above) lead to slightly 603 
increased failure rates and the “no glurp” algorithm being the most accurate at moderate to high 604 
FOI.  605 
 606 
3.4 Re-analysis of clinical data  607 
 608 
Clinical data from Rwanda (a relatively high transmission area) were re-analysed using the  proposed 609 
molecular correction algorithms (Table 2), and were highly consistent with our models i.e. the 610 
“WHO/MMV” algorithm produced the lowest estimated failure rate, followed by “no glurp”, then 611 
the “≥ 2/3 markers” algorithm, then the “allelic family switch” algorithm. The pattern was 612 
quantitively consistent: The “WHO/MMV” algorithm estimated failure rates to be around half that 613 
obtained by the “≥ 2/3 markers” algorithm. Results are similarly consistent with re-analysis of a trial 614 
from low transmission settings in Cambodia (Table 2). The impact of algorithm choice was not so 615 
large in Cambodia because FOI was low: 62 of the recurrences had matching alleles at all 3 loci so 616 
were presumably drug failures and would have been classified as such by all four algorithms. There 617 
were only 3 potential reinfections (all following DHA-PPQ treatment): 1 had no shared alleles at any 618 
locus so was classified as a reinfection under all four algorithms, but the other two patients shared 619 
alleles at both msp-1 and msp-2 and were only classified as reinfections under the “WHO/MMV” 620 
algorithm because no common alleles were noted at glurp. In contrast, the other algorithms all 621 
classified both patients as being drug failures. In summary, as in the high transmission data, the 622 
“WHO/MMV” algorithm had a higher tendency to classify recurrences as reinfections compared to 623 
the other algorithms. Note also that, consistent with Figure 4, the choice of algorithm makes little 624 
operational difference at low FOI: using the “WHO/MMV” algorithm identified 62 drug failures and 625 
three reinfections, while the other algorithms give 64 drug failures and one reinfections, a negligible 626 
increase in number of drug failures.  627 
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Finally, we reviewed clinical trials that reported failure rates based on no correction and the 628 
“WHO/MMV” algorithm (Table 3).  The magnitude of differences in failure rate estimates were 629 
similar to those noted in the results from our model where the non-corrected algorithm and the 630 
“WHO/MMV” algorithm produced the highest and lowest failure rate estimates respectively.  631 
 632 
4. Discussion 633 
 634 
The key message presented here is that none of the proposed algorithms using msp-1, msp-2 and 635 
glurp correctly classified all recurrent infections (Figure 3) nor is it likely that such an algorithm exists 636 
due to the limitations of the PCR correction process (11). The ability of each algorithm to accurately 637 
recover the true failure rate was dependent on the transmission intensity (quantified in these 638 
models by FOI) due to the differing propensity of each algorithm to misclassify reinfections as 639 
recrudescence (which occurred when alleles are shared by chance or a clone that later recrudesces 640 
was not observed in the initial sample); Figure 3. The 2-fold under-estimation of true failure rates 641 
that occurred at all FOI levels using the current “WHO/MMV” algorithm is a cause for considerable 642 
concern. This under-estimate occurred because this algorithm was extremely stringent – it did not 643 
misclassify any reinfections as recrudescence (Figure 3) – but did misclassify some recrudescences as 644 
reinfections when a clone that later recrudesced wasn’t detected in the initial sample (due to the 645 
issues inherent in the PCR methodology with detecting minority alleles and longer alleles). These 646 
issues are shared between algorithms; however, “no glurp”, “≥ 2/3 markers” and the “allelic family 647 
switch” algorithm are all less stringent and misclassified some reinfections as recrudescence (Figure 648 
3), which increased failure rate estimates and accounted – to some extent – for the under-649 
estimation of failure rates.     650 
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Key to identifying a methodology that gives consistently accurate estimated failure rates is to 651 
minimise and balance errors that arise from molecular correction, which are, in turn, influenced by 652 
factors including FOI, duration of follow-up, and sensitivity of the PCR protocols. Despite these 653 
concerns, these results show that operationally-important increases in accuracy of estimated failure 654 
rates for anti-malarial efficacy trials are achievable with alternate genotyping algorithms. It is 655 
undesirable to recommend different molecular correction algorithms for different ACTs and 656 
transmission intensity levels (as this would be likely to cause confusion), hence the approach of 657 
investigating multiple ACTs and varying transmission intensity through FOI to assess if a single 658 
algorithm may be identified that gives robust and accurate estimates. Based on the results 659 
presented here, it appeared that the “≥ 2/3 markers” algorithm was the most robust in areas of 660 
moderate to high transmission, and provided estimated failure rates close (typically within 2 661 
percentage units) to the true failure rate (Figure 2, Figure 4, [SM]).  662 
The other factor that can affect estimates of drug efficacy, given that molecular correction is 663 
imperfect, is the duration of follow-up. Recommended duration has gradually increased over the last 664 
20 to 30 years, with the objective of capturing all (or at least the majority) of recrudescences. 665 
However, the objective of clinical trials is not to capture every recrudescence, but to obtain accurate 666 
and robust estimates of efficacy. Figure 5 shows that in areas of moderate to high FOI, the penalty 667 
for detecting the last few recrudescences by extending the follow-up period was the inclusion of a 668 
much larger number of reinfections. These reinfections inflate the estimated failure rate due to the 669 
propensity of molecular correction algorithms to misclassify some reinfections as recrudescence 670 
(Figure 3). It is obviously preferable to have the shortest follow-up possible while retaining accuracy 671 
of failure rate estimates; based on the results shown in Figure 4, and analogous plots for failing AR-672 
LF and AS-MQ ([SM]),  using the “≥ 2/3 markers” algorithm provided accurate estimates using a 673 
follow-up of 28 days for AR-LF, 42 days for DHA-PPQ and 49 days for AS-MQ, all roughly in line with 674 
current WHO recommendations (2, 3). Importantly, the accuracy of the estimates with this algorithm 675 
appeared to be relatively robust to changes in transmission intensity, quantified in these models by 676 
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FOI (the “WHO/MMV” and “no glurp” algorithms were also robust to changes in FOI, but had an 677 
under-estimate of failure rate associated with them). Note that a different DHA-PPQ 678 
parameterization (i.e., one that is more prophylactic, see [SM]) favoured a longer follow-up period 679 
more in line with MQ which also has longer prophylaxis post-treatment. The trends across all drugs 680 
modelled are clear: it is highly likely that use of the current “WHO/MMV” algorithm will generate 681 
substantial (near two-fold) underestimates of failure rates and that switching to an alternative 682 
correction algorithm should be considered as matter of urgency.  683 
Technical problems with molecular correction approaches exist (identified and explained in, for 684 
example, (9, 11)) which gives rise to the temptation to simply ignore molecular correction and just 685 
use uncorrected data. The results presented here strongly suggest that appropriate use of molecular 686 
correction is essential. Trials conducted in areas of moderate to high transmission intensity, which 687 
are the areas where most malaria morbidity and mortality occur, analysed without molecular 688 
correction will lead to severe over-estimates of the true failure rate. This assertion is supported by 689 
clinical data (Table 3), which clearly shows that large discrepancies may arise in the absence of 690 
molecular correction. Ignoring molecular correction (i.e. non-PCR corrected algorithm in Figure 2 & 691 
Figure 4) only produced accurate estimates of failure rates when FOI is very low (a fact generally 692 
acknowledged in the literature (2, 3)).  However, caution must be taken even when using no-693 
correction in “low” transmission areas. Malaria transmission is highly focal and even if an area is, on 694 
average, very low transmission, it is plausible that most patients will be recruited from foci of high 695 
transmission where FOI may well be sufficient to invalidate estimates based on no-correction.  696 
The evaluation of different classification algorithms relied on simulated data. This was not ideal but 697 
there is no obvious alterative given that key parameters (including the vital one: true failure rate), 698 
cannot be directly observed in vivo.  Confidence in this approach was assured given the past success 699 
of pharmacological modelling to correctly reflect and predict clinical data e.g. (4, 14-16, 18, 22), and 700 
the consistency of the simulated results with in vivo Rwandan and Cambodian data-sets. We 701 
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acknowledge that our model may not reflect the in vivo parameters of these trials (though see 702 
discussion for the parameter space we covered in [SM]), however, the purpose of re-analysis of 703 
these data were to investigate the change in failure rates from us of proposed algorithms on in vivo 704 
data – analysis of trial results with these algorithms has not previously taken place. This re-analysis is 705 
not dependant on our model parameter space (nor vice versa), and all algorithms require the same 706 
data (the msp-1, msp-2 and glurp alleles (and families for the former two)); consequently, this re-707 
analysis showing similar trends to our modelled results is encouraging.  708 
  Focus has been on the current WHO-recommended marker loci msp-1, msp-2 and glurp and how 709 
they may be best used to distinguish recrudescences from reinfections; it would be straightforward 710 
to repeat these analyses for different types of molecular data, such as deep sequenced amplicons, 711 
microsatellites and SNP barcodes, and this is discussed further in [SM]. Notably, reduction of the 712 
minority detection threshold to 5% increased the failure rate estimates and altered which algorithm 713 
produced the most accurate estimate. We are confident that the length polymorphic markers do not 714 
have this level of sensitivity; we analysed this assumption solely to test its effect on our results, 715 
however, this threshold emulates more closely the use of amplicon sequencing where minority 716 
alleles are easier to detect, and we intend to test the accuracy of failure rate estimates with 717 
amplicon sequencing using a similar methodology in the future.  718 
There is concern in the literature that reinfections may share alleles with the initial infection purely 719 
by chance and that subsequent  misclassification of reinfections as recrudescence would lead to 720 
over-estimation of failure rates  (9). This could arise in areas of high transmission (7) as increased 721 
MOI leads to more alleles in the initial sample; these can later be shared with a reinfection purely by 722 
chance. It could also occur in low-transmission areas where genetic diversity is lower and there is 723 
more chance of a match by chance.  Importantly, we   do not observe large-scale over-estimation 724 
(e.g. the low impact of FOI on estimated failure rate using the “≥ 2/3 markers” algorithm in Figure 2 725 
 o
n
 July 24, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
32 
 
& [SM]) with increased transmission intensity with either a high MOI (Figure 4) or a low MOI [SM], 726 
suggesting these fears are unlikely to have a large impact in practice.  727 
In conclusion, our modelling approach and re-analysis of clinical data both suggest that more 728 
accurate and easily implemented algorithms are available to analyse clinical data and the field 729 
should consider implementing these methods. Which algorithm will perform best will depend on 730 
factors in the patient population/area - our results demonstrate this explicitly for transmission 731 
intensity (FOI) and follow-up length. The four algorithms investigated here are not mutually 732 
exclusive and are based on the same data. Our firm recommendation is that initial and recurrent 733 
samples should be genotyped at all three loci:  when using the current “WHO/MMV” algorithm, 734 
there is no need to genotype after a mismatch has occurred at one locus, so genotyping is often 735 
incomplete. These complete data would allow results obtained from all four algorithms be 736 
presented; this maintains consistency with previous analyses based on the “WHO/MMV” algorithm 737 
while also providing results that are likely to provide a substantially more robust estimate of malaria 738 
drug clinical failure rates. 739 
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Tables and Figures 918 
 919 
Table 1.  Molecular correction algorithms proposed to decide whether a patient re-presenting with a 920 
recurrent malaria infection during follow up is a recrudescence or a reinfection based on the WHO-921 
recommended genetic markers of msp-1, msp-2 and glurp. We also summarise the consequences of 922 
applying these algorithms for the analysis of clinical trials as quantified by our methodology: the 923 
failure rate estimates obtained from each algorithm are shown in Figure 2 & Figure 4.  924 
Table 2. Molecular correction with multiple algorithms from re-analysis of clinical trial data from 925 
Rwanda (a high transmission study sites) and Cambodia (a low transmission sites); full details of 926 
study sites and methodology are provided in methods 927 
Table 3: The need for molecular correction: a comparison of estimated drug failure rates obtained 928 
without correction vs with molecular correction performed according to the current WHO/MMV 929 
recommended algorithm. Failure rate was calculated as 1 minus the 28-day adequate clinical and 930 
parasitological response reported in the studies (data collated and provided by Drs Jörg Möhrle and 931 
Stephan Duparc). 932 
Figure 1:  Malaria parasite dynamics following treatment of a hypothetical patient and the need for 933 
molecular correction (adopted from Jaki et. al (2013) (25)). Note that parasites only become 934 
detectable in the patient’s blood by light microscopy once their numbers exceed a detection limit at  935 
108 parasites.  The blue solid line shows the declining concentration of drug post-treatment as it is 936 
eliminated by patient’s metabolism. This patient had four malaria clones detectable at time of 937 
treatment: The green lines represent initial clones that are cleared by the drug, the red line 938 
represents an initial clone that recrudesces. Reinfections periodically emerge from the liver during 939 
follow-up in cohorts of ~105 parasites per clone (orange line). The grey lines are reinfections that are 940 
cleared by the drug. The orange lines are reinfections that are not cleared and survive to reach 941 
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patency (i.e. increase in number to>108 at which point they are detectable by microscopy). The solid 942 
black line is the point during follow-up at which the patient first has a patent recurrent  infection i.e. 943 
has a parasitaemia sufficiently high that it is detectable by microscopy.  944 
Figure 2 : Analysis of simulated trial data for DHA-PPQ with a follow-up period of 42 days. Estimated 945 
failure rates are shown for the different algorithms of molecular correction (Table 1) as a function of 946 
Force of Infection (FOI) and are calculated using survival analysis.  Mutiplicity of Infection (MOI) is 947 
drawn from data from Tanzania – a relativley high transmission area.  948 
Figure 3: Figure showing the ability of the various molecular correction algorithms to correctly 949 
classify patients with recurrent malaria. The data are for DHA-PPQ with a 42-day follow-up obtained 950 
with a FOI of 8 (i.e. used to obtain the results shown at FOI=8 in Figure 2). Mutiplicity of Infection 951 
(MOI) is drawn from data from Tanzania – a relativley high transmission area.  The X-axis shows the 952 
true status of patients on the day of recurrence (i.e. reinfection or a recrudescence) and the colour-953 
coding shows how these patients were classified by each algorithm. The WHO/MMV recommended 954 
algorithm correctly classifies nearly all reinfections, but misclassifies around one third of 955 
recrudescences. The “no glurp” algorithm is similar to the WHO/MMV one; it misclassifies only a 956 
small number of reinfections, but misclassifies around a third of recrudescences. The “≥2/3” had 957 
fewer misclassifications and was also more balanced i.e. misclassified a similar proportion of both 958 
reinfections and recrudescences. Finally, the allelic family switch algorithm correctly classifies a large 959 
proportion of recrudescences but misclassifies around half of reinfections.  960 
Figure 4 : Analysis of simulated trial data for DHA-PPQ showing the impact of changing follow-up 961 
period with follow-up lengths of (A) 28 days, (b) 42 days (as in Figure 2), and (C) 63 days. Estimated 962 
failure rates are shown the different molecular correction algorithms (Table 1) as a function of FOI 963 
and calculated using survival analysis. Mutiplicity of Infection (MOI) is drawn from data from 964 
Tanzania – a relativley high transmission area. 965 
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Figure 5 : The true status of recurrent infections on each day of follow-up for a simulated trial of 966 
DHA-PPQ with a true failure rate of 12% and an FOI of 8. Mutiplicity of Infection (MOI) is drawn from 967 
data from Tanzania – a relativley high transmission area. The total height of the bars indicates the 968 
number of recurrent infections detected on that day of follow-up, and the color-coding shows the 969 
number of those recurrent infections that were truly recrudescent or reinfections. 970 
 971 
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Algorithm Reference Definition Consequences (identified in the model) 
No Correction  All recurrent infections classified as 
recrudescence 
Grossly over-estimates failure rate at higher FOI 
WHO/MMV (2) Initial and recurrent samples must have 
shared alleles at all three markers to be 
classified as recrudescence.  
Stringent conditions for recurrences to be classified as recrudescence means 
that around 50% of true recrudescence are misclassified as reinfections 
resulting in greatly underestimated failure rates. Most reinfections are 
correctly classified, so FOI has little impact on estimated failure rate 
No glurp (11) As for the WHO/MMV algorithm but 
based on two loci (i.e. msp-1 and msp-2; 
glurp is omitted as it is prone to 
genotyping errors).  
Largely identical to the WHO/MMV method 
≥ 2/3 markers (11) As for the WHO/MMV algorithm, but 
initial and recurrent samples must share 
alleles at least at two out of three 
markers to be classified as 
recrudescence.  
GeŶerally iŶterŵediate ďetweeŶ ͞Ŷo glurp͟ aŶd ͞alleliĐ faŵily switĐh͟ 
algorithms 
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Allelic family 
switch 
(11) Comparison initially based on msp-1 
and msp-2. Identical alleles observed at 
both markers indicate a recrudescence. 
Absence of shared alleles at both 
markers indicate a reinfection. If one 
marker shares alleles and one does not 
;i.e. the saŵple is ͞disĐordaŶt͟Ϳ, a 
complete allelic family shift in the non-
sharing marker is required to classify a 
recurrence as a reinfection 
Tendency to misclassify reinfections as recrudescences leads to a dependency 
on FOI and results in large overestimates of failure rates at higher FOI, though 
produces accurate failure rate estimates at low FOI.  
FOI = Force of Infection, our measure of transmission intensity. FOI is the mean number of malaria infections that emerge in an individual and would 
become patent in the absence of drug killing over the course of a year.  
Table 1.  Molecular correction algorithms proposed to decide whether a patient re-presenting with a recurrent malaria infection during follow up is a 
recrudescence or a reinfection based on the WHO-recommended genetic markers of msp-1, msp-2 and glurp. We also summarise the consequences of 
applying these algorithms for the analysis of clinical trials as quantified by our methodology: the failure rate estimates obtained from each algorithm for 
DHA-PPQ are shown in Figure 2 & Figure 4.  
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Country Drug*  Classification of 
recurrent infection 
WHO/MMV No glurp ≥ 2/3 markers Allelic family 
switch 
Rwanda AR-LF recrudescence 17 27 36 59 
reinfections 93 83 73 51 
DHA-
PPQ 
recrudescence 3 6 8 18 
reinfections 40 37 35 25 
Cambodia AS-AQ recrudescence 5 5 5 5 
reinfections 0 0 0 0 
DHA-
PPQ 
recrudescence 45 47 47 47 
reinfections 3 1 1 1 
AS-PYN recrudescence 12 12 12 12 
reinfections 0 0 0 0 
 
AS-AQ is artesunate plus amodiaquine; DHA-PPQ is dihydroartemisinin plus piperaquine; AR-LF is 
artemether plus lumefantrine. AS-PYN is artesunate plus pyronaridine. 
Table 2. Molecular correction with multiple algorithms from re-analysis of clinical trial data from 
Rwanda (a high transmission study sites) and Cambodia (a low transmission sites); full details of 
study sites and methodology are provided in methods 
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Drug tested Uncorrected vs corrected failure rates Country/yr Ref 
AR-LF 
AS-AQ 
54% vs 10% 
42% vs 10% 
Burkina Faso, 2014 (34) 
AS-AQ 17% vs 6% Congo, 2013 (35) 
AR-LF 22% vs 0% Tanzania, 2014 (36) 
AR-LF 13% vs 0% Benin, 2016 (37) 
AR-LF 9% vs 2% Mozambique, 2015 (38) 
AR-LF 2% vs 1% India 2015 (39) 
AR-LF 
AS-AQ 
16% vs 1% 
22% vs 5% 
Congo 2012 (40) 
 AR-LF, artemether plus lumefantrine; AS-AQ, artesunate plus amodiaquine 
 
Table 3: The need for molecular correction: a comparison of estimated drug failure rates obtained 
without correction vs with molecular correction performed according to the current WHO/MMV 
recommended algorithm. Failure rate was calculated as 1 minus the 28-day adequate clinical and 
parasitological response reported in the studies (data collated and provided by Drs Jörg Möhrle and 
Stephan Duparc). 
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